Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
INmune Bio, Inc.: INmune Bio Reports Statistically Significant ...
Inmune Bio Biotech company granted FDA fast track designation for ...
INmune Bio, Inc.: INmune Bio Inc. Announces 2025 Results and Provides ...
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s ...
INMB Earnings Q1 2026: INmune Bio Quarterly Results – SmartInvestorsDaily
INmune Bio Secures $19 Million Through Direct Offering - Investors Hangout
INmune Bio logo in transparent PNG and vectorized SVG formats
INmune Bio Announces Upcoming Webinar on New RDEB Treatment Data - Boca ...
INmune Bio unveils Phase 2 grey matter imaging data in AD | INMB Stock News
INmune Bio Partners with Cell and Gene Therapy Catapult
INmune Bio Inc. Announces Second Quarter 2025 Results,
Inmune Bio Advances Immunotherapy Pipeline with Phase 2 Completion ...
INmune Bio | Fierce Biotech
INmune Bio slumps on midstage fail for Alzheimer's drug | pharmaphorum
INmune Bio gets FDA alignment on XPro1595 Phase 2b/3 | INMB Stock News
INmune Bio Raises $19M in Direct Offering for Immunology Programs ...
INmune Bio Highlights DoD-Supported Data Showing XPro™ Reduces ...
INmune Bio Demonstrates Significant Improvement in Alzheimer’s Disease ...
INmune Bio Inc. | LinkedIn
Inmune Bio uses DN-TNF biologic to target soluble TNF to increase ...
INmune Bio Completes Commercial Manufacturing of RDEB Therapy | INMB ...
INmune Bio CORDStrom RDEB data webinar Feb. 26 | INMB Stock News
INmune Bio Partners with Imeka
Inmune Bio Files Investor Presentation with Key Data
INmune Bio Stock Slumps On 3M Share Offering Ahead Of Mid-stage Trial ...
Contact | Statesman-Examiner - INmune Bio Announces FDA Alignment on ...
INmune Bio Inc. on LinkedIn: David Moss Of INmune Bio: 5 Things I Wish ...
INmune Bio Resumes AD02 Trial for Alzheimer’s Disease - CTOL Digital ...
INmune Bio to Submit FDA BLA for CORDStrom in RDEB - The Dermatology Digest
INmune Bio Plunges 55.53% on Equity Offering, Clinical Trial Disappointment
INmune Bio International LTD | LinkedIn
Biotech INmune BIO (INMB) Collapses 60% after Alzheimer’s Trial Misses ...
Biotech Breakfast Brief: INmune Bio (INMB)
INmune Bio Inc. on LinkedIn: #womeninstem #womeninhealthcare # ...
INmune Bio Lags in PRISM Global Health Index Following Securities ...
Inmune Bio Reveals Promising XPro™ Trial Results - TipRanks.com
INmune Bio Inc. on LinkedIn: Targeting soluble TNF to attenuate ...
INmune Bio (INMB) Plunges 15.13% Amid Capital Raise
INmune Bio Phase 2 Alzheimer's Trial Results Coming Monday | INMB Stock ...
INmune Bio Shrinks Losses While Analysts See Upside Ahead - Finimize
INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy ...
INmune Bio Inc - WKN A2PCBU, ISIN US45782T1051 | DivvyDiary
Immune Bio Green Cell – BioGreenCell
INmune Bio Inc. (INMB) Announces $9.7 Million Registered Direct ...
INMune Bio establishes $65 million at-the-market offering
INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely
INmune Bio Plunges 10.52% Amid Clinical Trial Anticipation
INmune Bio Inc. on LinkedIn: #happynewyear2023 #alzheimersdisease #ad # ...
INmune Bio taps CGT Catapult for cell therapy production
Olusegun Abiola - Senior Scientist at INmune Bio | The Org
Omniscience and Inmune Bio Partner to Accelerate Alzheimer’s Drug Trial
INmune Bio Stock Quote INMB - Stock Price, News, Charts, Message Board ...
INmune Bio Inc. on LinkedIn: #parkinsons #parkinsonsdisease #alzheimers ...
INmune Bio Secures $19M: Can Strategic Capital Allocation Sustain Its ...
INmune Bio partners with Cell and Gene Therapy Catapult to scale up ...
INmune Bio Inc. on LinkedIn: #alz #alzheimers #alzheimersdisease #ad # ...
[8-K] INmune Bio Inc. Common stock Reports Material Event | INMB 8-K Filing
INmune Bio Inc. on LinkedIn: A groundbreaking study out of the Imperial ...
Raymond James Initiates Coverage of INmune Bio (INMB) with Outperform ...
INmune Bio Inc. on LinkedIn: Thank you Jason McCarthy, PhD for kindly ...
Scotiabank Reaffirms Sector Underperform Rating for INmune Bio (NASDAQ ...
INmune Bio sets Q3 2025 results call for Oct 30 at 4:30 ET | INMB SEC ...
INmune Bio looks to help treat Alzheimer's disease and cancer after IPO ...
OmniScience and INmune Bio Partner for Alzheimer’s Trial
INmune Bio partners with CGT Catapult for #CellTherapy | Cell and Gene ...
Ed Baracchini - Member Board Of Directors at INmune Bio | The Org
INmune Bio Soars 10.68% Awaiting FDA Decision
INmune Bio (INMB) - Market capitalization
INmune Bio Inc (INMB) Q2 2025 Earnings Call Highlights: Promisin
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 ...
BTIG Downgrades INmune Bio (INMB)
INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst ...
OmniScience and INmune Bio Join Forces to Transform Global Alzheimer’s ...
At SITC 2023, INmune Bio Inc. shared preclinical findings indicating ...
INmune Bio Inc.
INmune Bio | STAT
Respuesta-inmune.pdf
Is INmune Bio’s Breakthrough Turning Heads?
Corporate Presentation
INmune Bio’s Successful First Commercial Run of Cordstrom™ | Moe Alsumidaie
INmune Bio’s Future: Buying, Holding, or Selling?
INmune Bio’s Stock Tanks: Worth Considering?
When Every Hour Counts: How Cryoport Systems Rapidly Mobilized to ...
INmune Bio’s Promising Preclinical Results: A Market Game-Changer?
INmune Bio's Cancer Drug Succeeds in Prostate Cancer Trial, Advances to ...
INmune Bio's $19M Raise: A Strategic Play to Fuel Alzheimer's Breakthrough?
Why INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025 - Insider Monkey
What are the Porter's Five Forces of INmune Bio, Inc. (INMB ...
INmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to ...
INmune Bio’s $4.8 Million Common Stock Offering – Global Legal Chronicle
INmune Bio's XPro: Can Subgroup Success Overcome Phase 2 Disappointment?
NeuLiv(INmune Bio, Inc.) - Drug Targets, Indications, Patents - Synapse
Maxim Group
Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West ...
INmune Bio's INKmune Hits End Points in mCR Prostate Cancer Trial ...
Jones Healthcare and Technology Innovation Conference
What to Expect from INmune Bio's Earnings
INmune Bio’s Alzheimer’s drug fails Phase 2; BridgeBio sells some ATTR ...
INmune Bio, Inc. - PRISM MarketView
INmune Bio: Alzheimer's Disease Treatment Lottery Ticket (NASDAQ:INMB ...
About Us
Contact Us
Our science
Patients
First Patient Dosed in INmune Bio’s Phase1b Trial Testing XPro1595 Anti ...
INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid ...
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance ...
%20logo%20white.webp?width=300&height=192&name=INmune%20Bio%2c%20Inc.%20(INMB)%20logo%20white.webp)
_Maxim%202024%20Healthcare%20Virtual%20Summit_Tile%20copy.webp?width=440&height=300&name=INmune%20Bio%2c%20Inc.%20(INMB)_Maxim%202024%20Healthcare%20Virtual%20Summit_Tile%20copy.webp)
